REFERENCES

1. Global cancer cases reach 14 million, World Health Organization says, BBC News. (2013). Available from: https://www.bbc.com/news/health-25346639 [Last accessed on 11 Nov 2021].

2. Worldwide cancer statistics, Cancer Res. UK. (2015). Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer [Last accessed on 11 Nov 2021].

3. Boehmerle W, Zhang K, Sivula M, et al. Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc Natl Acad Sci U S A 2007;104:11103-8.

4. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell 2014;25:2677-81.

5. Priyadarshini K, Keerthi A U. Paclitaxel against cancer: a short review. Med chem 2012;2:139-41.

6. Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother 2002;3:755-66.

7. Ramalingam S, Belani CP. Paclitaxel for non-small cell lung cancer. Expert Opin Pharmacother 2004;5:1771-80.

8. Ghamande S, Lele S, Marchetti D, Baker T, Odunsi K. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer 2003;13:142-7.

9. Perez EA. Paclitaxel in breast cancer. Oncologist 1998;3:373-89.

10. Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 2001;15:525-45.

11. Glass-Marmor L, Beitner R. Taxol (paclitaxel) induces a detachment of phosphofructokinase from cytoskeleton of melanoma cells and decreases the levels of glucose 1,6-bisphosphate, fructose 1,6-bisphosphate and ATP. Eur J Pharmacol 1999;370:195-9.

12. Zhao M, Lei C, Yang Y, et al. Abraxane, the nanoparticle formulation of paclitaxel can induce drug resistance by up-regulation of P-gp. PLoS One 2015;10:e0131429-e.

13. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-95.

14. Yang H, Zhang Q, He J, Lu W. Regulation of calcium signaling in lung cancer. J Thorac Dis 2010;2:52-6.

15. Büsselberg D, Florea A-M. Targeting intracellular calcium signaling ([Ca²⁺]_i) to overcome acquired multidrug resistance of cancer cells: a mini-overview. Cancers 2017;9:48.

16. Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta Pharm Sin B 2017;7:3-17.

17. Rossier MF. T-type calcium channel: a privileged gate for calcium entry and control of adrenal steroidogenesis. Front Endocrinol 2016;7:43.

18. Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem 2012;287:31666-73.

19. Tajada S, Villalobos C. Calcium permeable channels in cancer hallmarks. Front Pharmacol 2020;11:968.

20. Taylor JT, Zeng XB, Pottle JE, et al. Calcium signaling and T-type calcium channels in cancer cell cycling. World J Gastroenterol 2008;14:4984-91.

21. Antal L, Martin-Caraballo M. T-type calcium channels in cancer. Cancers (Basel) 2019;11:134.

22. Kumari N, Gaur H, Bhargava A. Cardiac voltage gated calcium channels and their regulation by β-adrenergic signaling. Life Sci 2018;194:139-49.

23. Wang CY, Lai MD, Phan NN, Sun Z, Lin YC. Meta-analysis of public microarray datasets reveals voltage-gated calcium gene signatures in clinical cancer patients. PLoS One 2015;10:e0125766.

24. Valerie NC, Dziegielewska B, Hosing AS, et al. Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells. Biochem Pharmacol 2013;85:888-97.

25. Dziegielewska B, Casarez EV, Yang WZ, Gray LS, Dziegielewski J, Slack-Davis JK. T-type Ca²⁺ channel inhibition sensitizes ovarian cancer to carboplatin. Mol Cancer Ther 2016;15:460-70.

26. Kraus RL, Li Y, Gregan Y, et al. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J Pharmacol Exp Ther 2010;335:409-17.

27. Kumari N, Bhargava A, Rath SN. T-type calcium channel antagonist, TTA-A2 exhibits anti-cancer properties in 3D spheroids of A549, a lung adenocarcinoma cell line. Life Sci 2020;260:118291.

28. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 2012;9:676-82.

29. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-5.

30. V S S, P V M. Degradation of Poly(ε-caprolactone) and bio-interactions with mouse bone marrow mesenchymal stem cells. Colloids Surf B Biointerfaces 2018;163:107-18.

31. Origin(Pro), OriginLab Cooperation, Northampton, MA, USA. Available from: https://www.originlab.com/index.aspx?go=Company&pid=1130 [Last accessed on 11 Nov 2021].

32. Tram N, Leroy P, Bellucci L, et al. Intracellular concentrations of Fura-2 and Fura-2/AM in vascular smooth muscle cells following perfusion loading of Fura-2/AM in arterial segments. Cell Calcium 1995;18:420-8.

33. Reger TS, Yang ZQ, Schlegel KA, et al. Pyridyl amides as potent inhibitors of T-type calcium channels. Bioorg Med Chem Lett 2011;21:1692-6.

34. Kumari N, Dalal V, Kumar P, Rath SN. Antagonistic interaction between TTA-A2 and paclitaxel for anti-cancer effects by complex formation with T-type calcium channel. J Biomol Struct Dyn 2020:1-12.

35. Dziegielewska B, Gray LS, Dziegielewski J. T-type calcium channels blockers as new tools in cancer therapies. Pflugers Arch 2014;466:801-10.

36. Keir ST, Friedman HS, Reardon DA, Bigner DD, Gray LA. Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. J Neurooncol 2013;111:97-102.

37. Eiro N, González L, Martínez-Ordoñez A, et al. Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis. Cell Oncol (Dordr) 2018;41:369-78.

38. O'Reilly D, Buchanan P. Calcium channels and cancer stem cells. Cell Calcium 2019;81:21-8.